Fusing a non-pathogenic, structurally modified version of the Sda1, SLO, or Scl1 to a TAA like mesothelin, a prominent TAA in PDAC (74, 87) could be beneficial in inducing anti-tumor responses. Here, MSLN is linked to neoplasm.